Thymopoietin

Thymopoietin is a thymic peptide hormone historically described as one component of thymic extracts that modulate the immune system. It was identified in early work on thymic humoral factors and was considered part of the network of thymic peptides that influence T-lymphocyte development and function, alongside thymosin and thymulin.

Biological activity attributed to thymopoietin included promotion of thymocyte maturation, enhancement of T‑cell proliferation, and stimulation of cellular immune responses in experimental systems. However, preparations labeled as thymopoietin often contained mixtures of peptides, and there was substantial variation in activity between sources. As purification and molecular characterization advanced, the field recognized that multiple peptide species contributed to thymopoietic activity, and the single, well-defined entity known as thymopoietin became less clearly defined in modern terms.

Biochemistry and nomenclature: The identity of thymopoietin has varied across studies, with different laboratories reporting different peptides in thymus-derived fractions. Consequently, contemporary immunology has moved toward naming specific, characterized thymic factors (for example, thymosin alpha‑1 and thymulin) rather than maintaining a single unambiguous thymopoietin entity.

Clinical relevance: Thymic peptides were explored as potential immune therapies, particularly for immunodeficiency and cancer. Thymopoietin itself is not used as a standard treatment today, and there is limited high-quality evidence supporting a clear clinical benefit. Research on thymic factors has shifted toward understanding peptide hormones and cytokines with more defined structures and mechanisms.

See also: thymosin, thymulin, thymic stromal lymphopoietin.